Devah Therapeutics is a CNS drug development company focused on redeploying clinically validated molecules using modern exposure optimization and capital-efficient regulatory strategies.

Our lead program is an oral, non-sedating, non-addictive CNS agent with more than four decades of clinical use outside the U.S. Devah is advancing the molecule for conditions marked by persistent symptoms and maladaptive CNS signal amplification.

Our goal is simple: build a disciplined CNS drug company that translates proven clinical signal into durable, protected value—without unnecessary complexity or burn.

Devah Therapeutics Corporation

Org chart

Teams

Offices